In July, a mail carrier in Phoenix, Arizona, claimed to have cooked a steak to an internal temperature of 142 degrees Fahrenheit—medium rare—on the dashboard of his delivery vehicle, which doesn't have air conditioning.
Universal health coverage depends on affordable medicines. But pushing down prices without also investing in quality assurance will increase the sale of substandard and falsified drugs, warns Elizabeth Pisani.
Science can and does change humanity. Yet while we live in an age of extraordinary advances, profound health challenges remain. Global health emergencies such as rapidly rising drug-resistance, epidemic threats from diseases known and unknown, mental health, and the escalating climate crisis are a threat to us all.
A fridge designed for vaccines and medicines has “harnessed the power of nature” to keep its contents cold, even with intermittent access to electricity.
Substandard and falsified medications pose significant risks to global health. Nearly one in five antimalarials circulating in low- and middle-income countries are substandard or falsified. We assessed the health and economic impact of substandard and falsified antimalarials on children under five in Nigeria, where malaria is endemic and poor-quality medications are commonplace.
To tackle one of the most urgent public health crises facing the world today – antimicrobial resistance (AMR) – universal health coverage (UHC) must be realized. It’s time to take action by ensuring that everyone has access to safe, effective, quality-assured medicines.
When a poor country becomes wealthier, it's a good thing, right? Not if the country is trying to buy essential medicines.
Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-and middle-income countries
The rapid globalisation of the pharmaceutical production and distribution has not been supported by harmonisation of regulatory systems worldwide. Thus, the supply systems in low-income and middle-income countries (LMICs) remain exposed to the risk of poor-quality medicines. To contribute to estimating this risk in the private sector in LMICs, we assessed the quality assurance system of a convenient sample of local private pharmaceutical distributors.